Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
Other Sizes |
|
ln Vitro |
Aflibercept (500 μg/mL; 24 h and 7 d) does not exhibit any toxicity on RPE cells in either the trypan blue exclusion experiment or the MTT assay[1]. In the confluent RPE cell layer with three wounds, Aflibercept (500 μg/mL; 24 h) exhibits a statistically significant effect on wound healing when compared with control[1]. When compared to the untreated control, aflibercept (500 μg/mL; 7 d) exhibits a noticeably reduced phagocytosis of opsonized latex beads[1]. Aflibercept (1 and 10 μg/mL; 10 h) decreases angiogenesis and permeability, two VEGF-regulated processes, which in turn inhibit VEGF signaling[2].
|
---|---|
ln Vivo |
In obese mice, aflibercept (10 mg/kg; 3 h post-middle cerebral artery occlusion; MCAO)) increases poststroke survival by reducing stroke-induced VEGF-A and VEGFR2 expression, brain edema, and BBB disruption[2]. Aflibercept (18.2 mg/kg and 36.4 mg/kg; intraperitoneally once) influences mice's blood pressure, generation of ROS, and eNOS[3].
|
Animal Protocol |
Animal/Disease Models: Male C57BL/6 mice[3]
Doses: 18.2 mg/kg and 36.4 mg/kg Route of Administration: intravenous (iv) injection; 18.2 mg/kg and 36.4 mg/kg once Experimental Results: Rapidly and dose-dependently elevated BP in mice and markedly impaired endothelial-dependent relaxation (EDR) and resulted in NADPH oxidases 1 (NOX1)- and NADPH oxidases 4 (NOX4 )-mediated generation of ROS, diminished the activation of protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) concurrently with a reduction in nitric oxide (NO) production and elevation of ET-1 levels in mouse aortas. |
References |
|
CAS # |
862111-32-8
|
---|---|
Related CAS # |
Aflibercept (VEGF Trap);862111-32-8
|
Appearance |
Colorless to light yellow liquid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.